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Key Clinical Message
Autosomal recessive spastic ataxia of Charlevoix-Saguenay is a rare disorder
outside Quebec causing childhood-onset cerebellar ataxia, peripheral neuropa-
thy, and pyramidal tract signs. A Finnish family with milder form of ARSACS
was found to harbor three mutations, p.E1100K, p.N1489S, and p.M1359T, in
SACS gene. The mutations segregated with the disease.
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Introduction
ARSACS is a recessive neurodegenerative disease causing
childhood-onset cerebellar ataxia, peripheral neuropathy,
and pyramidal tract signs [1]. It was first described in the
Charlevoix-Saguenay-Lac-Saint-Jean region of Quebec
where the estimation of frequency of carriers is 1 of 22
[2]. The disease-causing gene, SACS, encodes a large pro-
tein sacsin that is expressed in brain motor systems and
in various other tissues [3]. More than 100 mutations in
SACS have been identified worldwide [4–6]. The protein’s
function is still largely unknown, although its role in the
regulation of mitochondrial physiology has been proposed
[7, 8]. Recent functional and molecular analyses of mito-
chondrial activity in fibroblasts obtained from ARSACS
patients suggested involvement of oxidative stress and
mitochondrial dysfunction in the pathogenesis of the
disease [9, 10].
The first symptoms are typically balance problems
before the age of 5 years in most cases, followed by
spasticity and axonal-demyelinating sensorimotor periph-
eral neuropathy in their teens. The progression is slow;
patients become wheelchair-bound approximately in
their 4th decade [11]. Additional features include hyper-
myelinated retinal fibers, urge incontinence, and erectile
dysfunction. Cerebellar vermis atrophy and linear hypo-
intensities in the pons are typical early findings [12,
13]. Not all patients display the classic triad; occasional
atypical and late-onset forms of ARSACS have been
reported, and recently, SACS mutations have been iden-
tified in a few patients with nonprogressive congenital
ataxia [9, 14].
We report here the first Finnish ARSACS family with
compound heterozygous mutation in SACS that causes
the classic triad phenotype, although with later onset and
slower progression than in most reported cases.
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Methods
The patients
A Finnish family with four affected siblings was examined
and followed up for more than 30 years. The clinical symp-
toms were classified as spastic ataxia, although two brothers
were first diagnosed with Charcot–Marie–Tooth (CMT) dis-
ease due to distal weakness and electrophysiology findings.
Two other siblings and the parents were healthy (Fig. 1A).
The patients were regularly examined by neurologists and
investigated by nerve conduction velocities (NCV), elec-
tromyogram (EMG), brain imaging and the proband also by
sural nerve biopsy and two muscle biopsies. Two patients
underwent ophthalmic examinations. None of the patients
had intellectual problems, visual symptoms, or epilepsy.
Genetic evaluation
DNA was extracted from leukocytes by standard methods.
The DNA sample of the proband was used for enrich-
ment of a sequencing library by NimbleGen SeqCap EZ
Human Exome v2.0. Paired-end sequencing (100 bp) was
performed using Illumina HiSeq 2000 sequencer with a
sequencing depth of 30X. Sequence reads were aligned to
the human reference genome (UCSC hg19) using the
Burrows–Wheeler aligner [15]. Variant calling was made
with Genome Analysis Toolkit. The data were visualized
with Integrative Genomics Viewer [16]. From the
sequencing data to further analysis were selected all the
exons and exon–intron borders of the following genes
known to be associated with recessive ataxia: FXN, TTPA,
C10orf72, APTX, SETX, SYNE1, ADCK3, TDP1, SIL1,
POLG, ATM, MRE11A, SACS, PHYH, and PEX7. DNA
samples of the other siblings (three affected, two unaf-
fected) were used to study the segregation of the variants
detected in the proband by Sanger sequencing.
The study was approved by the IRB of Tampere Univer-
sity Hospital. All participants provided appropriate consent.
Results
Family description
The proband (II:2), a-63-year-old female, presented with
progressive ataxic gait starting at age 25 (Table 1). She had,
however, experienced mild problems with balance since her
teens. The first examination at age 30 found mild dysarthria,
mild horizontal nystagmus, and slight intention tremor in
the limbs. Achilles and brachioradialis reflexes were absent,
but Babinski sign was present. Distal muscles in the lower
limbs were atrophic, and gait was spastic ataxic. Spasticity,
ataxia, and problems with balance steadily progressed and
led to wheelchair confinement at age 43.
Electrophysiological studies showed decreased sensory
and motor NCVs. At age 30, muscle and sural nerve
biopsies were performed with normal histology. Five years
later, a new muscle biopsy showed mild neurogenic
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Figure 1. Pedigree of the family (A) and electropherograms from Sanger sequencing (B).
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findings: scattered angular and atrophic fibers, and fiber-
type grouping. Genetic analyses at that time excluded
CMT1A and spinocerebellar ataxia SCA1.
Her brother (II:1) had been more thoroughly investi-
gated at age 26 due to muscle weakness and problems
with balance starting at school age. On electrophysiology,
NCVs were decreased leading to a diagnosis of CMT.
However, spasticity soon became evident, as did progres-
sive ataxia of all limbs. He became wheelchair-bound at
age 39 and, at that time, marked spastic paraparesis and
atrophy in all limbs were noted. He died 25 years later of
pneumonia. Patient II:4 experienced lower limb weakness
and balance problems since age 6. He was later diagnosed
with spinocerebellar ataxia and polyneuropathy. At age
36, he had normal strength in the upper limbs but gener-
alized weakness in the lower limb muscles. Gait was ataxic
with unsteady balance; he became wheelchair-dependent
at age 33. At the most recent examination (age 59), the
strength and coordination in the upper limbs were still
within normal range, although lower limbs, eye move-
ments, and speech were severely ataxic. Spasticity was
marked in the lower limbs. The youngest of the siblings
(II:6) presented with distal lower limb weakness and
ataxic gait at the age of 18. The progression of the disease
has been slow; at age 54, there were marked weakness in
the lower limbs and moderate ataxia in the upper limbs.
Severe spasticity in the lower limbs led to intrathecal
baclofen treatment, but she is still ambulant with a walker
and uses a wheelchair occasionally.
In addition, all affected siblings had dysarthric speech,
saccadic eye movement and nystagmus, pes cavus, and
hammertoes. Distal areflexia was evident in two patients,
all reflexes were absent in one patient, and Babinski sign
present in two and a loss of vibration sense in three. One
patient had symptoms indicative of neurogenic bladder.
Ophthalmic examination revealed thickening of the reti-
nal nerve fiber layer in one patient, and the other had
normal findings (Fig. 2A).
The proband had normal findings on brain imaging at
age 35. She did not undergo further imaging studies. In
patient II:6, MRI was performed at age 43 (Fig. 2B),
showing cerebellar atrophy that had slightly progressed in
five years. Cortical atrophy was present in frontal and
parietal lobes as well as typical linear hypo-intensities in
the pons. More advanced changes were evident in II:4 at
age 59 (Fig. 2C) and in II:1 at age 41.
Molecular genetics
Exome sequencing of patient II:2 revealed three rare
heterozygous mutations in SACS. All three mutations were
confirmed by Sanger sequencing (Fig. 1B). Of the muta-
tions, c4466A>G p.N1489S has a low frequency (0.0046) in
normal population, whereas the other two are novel. Sanger
sequencing analysis of the other siblings indicated that
mutation combination c.[3298G>A;4466A>G]; [4076T>C]
p.[E1100K;N1489S]; [M1359T] segregated with the disease
(Fig. 1A).
Discussion
ARSACS is increasingly recognized worldwide and consid-
ered to be one of the most frequent types of spastic ataxia
after Friedreich ataxia and ataxia telangiectasia [5, 9].
Table 1. Clinical characteristics of the family.
Pat Age/sex
Age of
onset
Clinical symptoms
at presentation
Cerebellar
ataxia Spasticity Polyneuropathy
Muscle
weakness/
atrophy Ambulation Brain CT/MRI
II:1 65*/M 10 Lower limb
weakness
and spasticity
Yes Yes,
marked
Sensorimotor
demyelinating
Marked spastic
paraparesis and
atrophy in all
limbs
WCB since
age 39
CT: Cortical
atrophy in
cerebrum,
cerebellum,
brain stem
II:2 63/F (15) 25 Poor balance
since teens;
ataxic gait
since age 25
Yes. Gait, UL
and LL l.a.
Yes, LL Sensorimotor
demyelinating
Distal lower
legs, hands
WCB since
age 45
CT: normal at
age 35
II:4 59/M 6 Distal lower limb
weakness
Yes. Gait, LL,
speech
Yes, LL
severe
Sensorimotor
demyelinating
LL weakness WCB since
age 33
MRI: Cortical
atrophy
II:6 54/F 18 Distal lower
limb
weakness,
ataxic gait
Yes. LL:
marked
UL:
moderate
Yes Sensorimotor
demyelinating
Marked
weakness
in LL
Walker, WCh
when needed
since age 52
MRI: Cortical
atrophy in
cerebrum,
cerebellum
*Age at death; UL, upper limbs; LL, lower limbs; WCB, wheelchair bound; WCh, wheelchair.
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Nevertheless, our family is the first ARSACS family
identified in Finland.
The patients harboring two founder mutations identi-
fied in Quebec have manifested with the uniform presen-
tation of unsteadiness and ataxia in early childhood,
followed by spasticity during childhood and neuropathy
during the teens [1–3]. In other populations with differ-
ent pathogenic mutations, the phenotype is still quite
constant, although occasional later onset and atypical
forms have been identified [4–9, 14]. The age of onset
and the presenting symptoms as well as the rate of pro-
gression varied in our family. Problems with gait started
in adolescence in two siblings, whereas another two had
lower limb weakness since early school years, leading to
the initial diagnosis of CMT. The final diagnosis based on
clinical symptoms and findings was therefore challenging
and, in fact, early on one clinical geneticist dismissed
ARSACS as a possible cause of the family’s disease in his
consultation.
Retinal nerve fiber layer hypermyelination and cerebel-
lar vermis atrophy as well as hypo-intensities in the pons
are considered the early hallmarks of the disease, and
together with typical clinical features, they could help in
reaching accurate diagnosis early [12, 13, 17]. In one sib-
ling, there was a finding of hypermyelination in retina,
and in another, hypo-intensities were present in the pons
in addition to cerebellar atrophy, thus completing the
clinical phenotype.
(A)
(B)
(C)
Figure 2. Imaging findings of the patients. Funduscopic findings of patient II:4 (A). There is thickening of the myelinated layers of retina (arrow).
Patient II:2 underwent brain imaging at age 43 (B). There is cerebellar atrophy, and it has slightly progressed since the last imaging five years
previously (not shown). Cortical atrophy is seen in frontal and parietal lobes and linear hypo-intensity in the pons (arrow). Brain MRI of patient II:4
(C) shows more advanced cortical atrophy of cerebrum and cerebellum.
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We identified three mutations in SACS segregating in
the family. None of these were previously reported in
ARSACS, but based on segregation analysis, the novel
p.M1359T mutation is a disease-causing allele. Two other
mutations p.E1100K and p.N1489S are on the same allele,
and it cannot be concluded which one is disease causing,
but the allele as such is recessively pathogenic. According
to the frequency in normal population and mutation pre-
diction program, MutationTaster [18], p.E1100K is more
likely pathogenic, but without further functional studies,
this cannot be determined. Of the amino acids mutated
in our patients (p.E1100, p.M1359, and p.N1489),
p.N1489 is located in the second SRR domain of sacsin
protein, whereas the other two are located outside the
described domains. At least two missense mutations,
p.D168Y and p.R2703C, known to be located in SRR
domain have been identified to cause spastic ataxia of
Charlevoix-Saguenay disease phenotype [4, 19]. Of these,
p.D168Y has been reported to abrogate the ability of the
sacsin protein to hydrolyze ATP [20]. However, because
it is uncertain whether p.N1489S is pathogenic or not, its
impact on protein function is difficult to predict.
The classic triad, cerebellar ataxia, peripheral neuropa-
thy, and pyramidal tract signs, was evident in our family
and compatible with ARSACS, although disease onset was
later and progression was slower than in most reported
cases. Many of the previously reported ARSACS muta-
tions have been nonsense or frameshifts which may be a
hint of genotype–phenotype aspects regarding severity,
although no clear genotype–phenotype correlations have
been found [6, 9]. Anyway, it is important to recognize
the typical symptoms and to complement the triad with
the more specific findings in the pons and retina to reach
early and accurate diagnosis.
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